IN BRIEF: Bayer notes positive new data for finerenone

Bayer AG - Leverkusen, Germany-based pharmaceutical company - Notes positive new data for ...

Alliance News 4 April, 2022 | 6:09PM
Email Form Facebook Twitter LinkedIn RSS

Bayer AG - Leverkusen, Germany-based pharmaceutical company - Notes positive new data for finerenone in patients with a combination of atherosclerotic cardiovascular disease, chronic kidney disease and type 2 diabetes. Company says new data indicates that, compared to a placebo, finerenone consistently reduced the risk of cardiovascular and kidney outcomes.

"We are delighted to see that finerenone shows cardiovascular and kidney benefits in a broad range of patients with chronic kidney disease and type 2 diabetes, particularly those with atherosclerotic cardiovascular disease, who are at the highest risk of death," says Christian Rommel, head of Research & Development at Bayer.

Current stock price: EUR65.07

12-month change: up 21%

By Heather Rydings; heatherrydings@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Bayer AG 26.25 EUR 0.65

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures